Cosmos Health Files New AI-Driven Patent Application for Multiple Sclerosis Treatment, Targeting $25 Billion+ Global Market

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) has filed a patent application (N2039644) for a multiple sclerosis (MS) treatment, leveraging its AI-powered Cloudscreen drug repurposing platform. The initiative stems from the company's collaboration with Cloudpharm and the National Hellenic Research Foundation, supported by NLO's pharma patent experts.

The patent application is based on data-driven in silico evidence and simulations, along with experimental validation, identifying a unique mechanism of action in a repurposed marketed drug for MS treatment. This development targets the growing MS market, which was valued at $25.94 billion in 2023 and is expected to grow at a 5.9% CAGR from 2024 to 2030.

Multiple sclerosis, affecting 2.9 million people globally as of 2023, is a chronic autoimmune disorder impacting the central nervous system. The global market growth is driven by therapeutic advancements, increased healthcare investments, and ongoing research addressing unmet patient needs.

Positive

• Patent application filed for MS treatment using AI-driven drug repurposing technology
• Targeting $25.94 billion global MS treatment market with 5.9% projected CAGR (2024-2030)
• Strategic partnership with Cloudpharm and National Hellenic Research Foundation

Negative

• None.

Insights

Biotech Patent Analyst

Cosmos Health's patent filing for Multiple Sclerosis treatment merits careful analysis from multiple angles. The company's approach of using AI-driven drug repurposing is particularly noteworthy, as it could significantly reduce the traditional $1-2 billion cost and 10+ year timeline typically associated with new drug development.

The strategic value lies in three key aspects:

• The choice of drug repurposing leverages existing safety data and could accelerate the regulatory pathway, potentially reducing development time by 3-5 years
• Partnership with Cloudpharm and the National Hellenic Research Foundation provides important research infrastructure without significant capital investment
• Targeting the $25.94 billion MS market with a 5.9% CAGR offers substantial revenue potential, even with modest market penetration

However, investors should consider several critical factors. The company's market cap of $16.5 million raises questions about its ability to fund clinical trials, which typically cost $30-50 million through Phase III. Additionally, the MS market is dominated by established players like Biogen and Novartis, suggesting potential licensing deals might be a more realistic outcome than independent commercialization.

The patent application's focus on a 'unique mechanism of action' for a repurposed drug could be particularly valuable if it addresses current treatment gaps or offers improved efficacy. However, the path from patent filing to marketable treatment remains long and complex, requiring substantial capital investment and clinical validation.

Market Research Analyst

The Multiple Sclerosis treatment market presents a complex landscape with significant opportunities and challenges. The increase in global MS prevalence to 2.9 million patients in 2023 reflects a growing addressable market, driven by improved diagnosis rates and longer patient survival.

Key market dynamics include:

• Premium pricing potential, with current MS therapies often commanding $60,000-80,000 annual treatment costs
• Strong reimbursement coverage in major markets, particularly in the US and EU
• Increasing demand for novel treatment mechanisms, especially for progressive MS forms
• Growing focus on personalized medicine approaches

While the projected 5.9% CAGR through 2030 indicates sustained growth, market entry barriers are substantial. The MS treatment landscape is highly competitive, with established players holding strong patent positions and extensive clinical data. Cosmos Health's AI-driven approach could provide a competitive edge, but market success will likely depend on demonstrating superior efficacy or safety profiles compared to existing treatments.

CHICAGO, IL / ACCESS Newswire / February 5, 2025 / Cosmos Health Inc. ("Cosmos Health" or the "Company")(NASDAQ:COSM), a diversified, vertically integrated global healthcare group engaged in innovative R&D, owner of proprietary pharmaceutical and nutraceutical brands, manufacturer and distributor of healthcare products, and operator of a telehealth platform, announced today the filing of a patent application for multiple sclerosis (MS), a disabling autoimmune disorder affecting millions worldwide.

The patent application, filed under Application Number N2039644, represents a significant step forward in the Company's intellectual property strategy. This milestone highlights Cosmos Health's strategic partnership with Cloudpharm and the National Hellenic Research Foundation, supported by the pharma patent expert team at NLO.

The patent is supported by data-driven in silico evidence and simulations generated by Cosmos Health's AI-powered Cloudscreen drug repurposing platform, coupled with robust experimental validation. Recent findings by Cosmos Health have demonstrated the potential of a repurposed marketed drug for treating MS, with the inventors identifying a unique mechanism of action.

These advancements underscore the Company's commitment to tackling the challenges of autoimmune diseases and providing innovative solutions to enhance patient care.

Multiple Sclerosis

Multiple sclerosis is a chronic autoimmune disorder that affects the central nervous system, causing a wide range of symptoms and significant disability. According to the Atlas of MS, the number of individuals living with MS globally has risen from 2.3 million in 2013 to 2.9 million in 2023. With its unpredictable progression, MS presents ongoing challenges for patients and healthcare providers alike.

Global Market Overview

According to Grand View Research, the global multiple sclerosis treatment market has been experiencing steady growth, driven by advancements in therapeutic options and a rising prevalence of the disease. The market was valued at approximately $25.94 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 5.9% from 2024 to 2030. This growth is fueled by the introduction of innovative therapies, increased healthcare investments, and ongoing research to address the unmet needs of MS patients.

Greg Siokas, CEO of Cosmos Health, stated: "This patent application is another important addition to our intellectual property portfolio and reflects our dedication to advancing innovative treatments for complex diseases. By focusing on multiple sclerosis, we are addressing a critical medical need and are committed to delivering impactful solutions for patients worldwide."

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements

With the exception of the historical information contained in this news release, the matters described herein, may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Statements preceded by, followed by, or that otherwise, include the words "believes," "expects," "anticipates," "intends," "projects," "estimates," "plans" and similar expressions or future or conditional verbs such as "will," "should," "would," "may" and "could", are generally forward-looking in nature and not historical facts, although not all forward-looking statements include the foregoing. These statements, involve unknown risks and uncertainties that may individually or materially impact the matters discussed, herein for a variety of reasons that are outside the control of the Company, including, but not limited to, the Company's ability to raise sufficient financing to implement its business plan, the impact of the COVID-19 pandemic and the war in Ukraine, on the Company's business, operations and the economy in general, and the Company's ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those described in the forward-looking statements contained herein. Readers are urged to read the risk factors set forth in the Company's filings with the SEC, which are available at the SEC's website (www.sec.gov). The Company disclaims any intention or obligation to update, or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Investor Relations Contact:

BDG Communications
cosm@bdgcommunications.com
+44 207 0971 653

SOURCE: Cosmos Health Inc.

View the original press release on ACCESS Newswire

FAQ

What is the market size for multiple sclerosis treatment that COSM is targeting?

The global multiple sclerosis treatment market was valued at $25.94 billion in 2023, with a projected CAGR of 5.9% from 2024 to 2030.

What is the patent application number for COSM's multiple sclerosis treatment?

Cosmos Health's patent application for multiple sclerosis treatment was filed under Application Number N2039644.

How many people globally are affected by multiple sclerosis according to COSM's report?

According to the Atlas of MS cited in the report, the number of individuals living with MS globally has increased from 2.3 million in 2013 to 2.9 million in 2023.

What technology is COSM using for its multiple sclerosis treatment development?

COSM is using its AI-powered Cloudscreen drug repurposing platform, which generates data-driven in silico evidence and simulations for drug development.

Who are COSM's partners in developing the multiple sclerosis treatment?

Cosmos Health is partnering with Cloudpharm and the National Hellenic Research Foundation, with support from NLO's pharma patent expert team.